Barclays analyst Peter Lawson maintained a Hold rating on Blueprint Medicines (BPMC – Research Report) today and set a price target of $105.00.
Reports Q4 revenue $2.27B, consensus $2.24B. “During the quarter, we continued to make progress on our capital-focused strategic initiatives, ...
The Dali disaster did not affect the Britannia P&I Club’s decision to push for a 7.5% increase in premiums for 2025, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback